Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Acquires Cell Sorting System from Propel Labs

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories has acquired a new cell sorting system from Propel Labs for an undisclosed amount, the Hercules, Calif.-based firm announced today.

Bio-Rad plans to begin shipping the benchtop sorting flow cytometer, called the S3 Cell Sorter, in January.

While cell sorting instruments are usually found in shared research service facilities because of their size, complexity, and maintenance, the S3 Cell Sorter will allow researchers to bring their cell sorting research onto their benchtops, Bio-Rad said.

"With this acquisition, we benefit from Propel Labs' years of expertise in cell sorting," Brad Crutchfield, president of the Life Science Group at Bio-Rad, said in a statement. "The S3 Cell Sorter fits in well with Bio-Rad's existing product workflow and will offer researchers greater access to targeting specific cells in their experiments and ultimately increasing the sensitivity of their assays."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.